Sanofi SA vs ProShares UltraPro Short QQQ ETF — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while ProShares UltraPro Short QQQ ETF trades at $40.47. The key difference: Sanofi SA pays a 5.5% dividend while ProShares UltraPro Short QQQ ETF pays none, and Sanofi SA is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| SNY | SQQQ | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $97.60 |
52-Week Low | $41.33 | $36.31 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →